Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm
| Autor: | Fahad D. Algahtani, Reem M. Ali, Rafat Zreiq, Asma M. Khemakhem, Bandar Alsaif, Najoua Haouas, Rawan M. Obeidat, Asma Ayyed Al-Shammary |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject MEDLINE Lopinavir Hydroxychloroquine Disease medicine.disease law.invention 03 medical and health sciences Pneumonia 0302 clinical medicine Randomized controlled trial 030202 anesthesiology law medicine Ritonavir Intensive care medicine business 030217 neurology & neurosurgery medicine.drug media_common |
| Zdroj: | Journal of Pharmaceutical Research International. :119-134 |
| ISSN: | 2456-9119 |
| Popis: | Coronavirus disease 2019 (COVID-19) is emerging contagious pneumonia due to the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It initially appeared in Wuhan China in December 2019 then rapidly spread worldwide and became a pandemic. For the time being, there is no specific therapeutic treatment for this disease. Herein, the "state-of-the-art" of treatment modalities was systematically reviewed and ultimately a practical therapeutic algorithm for the COVID-19 management was proposed. The systematic review was performed by using published articles retrieved from Science Direct, MEDLINE, and Scopus databases concerning this topic. Among 1060 articles collected from the different databases, 19 publications were studied in-depth and incorporated in this review. The most three frequently used medications for the treatment of COVID-19 was: the available anti-viral drugs (n= 9), the antimalarial hydroxychloroquine or chloroquine (n = 8), and the passive antibody transfer therapy (n = 2). Among all treatment modalities, antimalarial hydroxychloroquine ranked the highest cure rate. Therefore, this drug is considered as the first‐line of COVID-19 treatment. The second‐line treatment includes the lopinavir/ritonavir drugs combined with interferon β-1b and ribavirin. Finally, the third‐line treatments include the remdesivir drug and passive antibody transfer therapy. However, our review emphasis the urgent need for adequately designed randomized controlled trials, enabling a more significant comparison between the most used treatment modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|